Accelerating Oncology Development Through Early-Stage Hubs in South Korea and Taiwan
Executive Summary | March 2026
Unlock insights from global experts on optimizing early-phase oncology trials in Asia.
Overview
Early-phase oncology development is becoming increasingly complex—requiring faster timelines, stronger investigator engagement, and smarter site selection. While Asia-Pacific (APAC) has long been a destination for clinical trials, South Korea and Taiwan are emerging as powerful early-stage hubs offering distinct strategic advantages.
This executive summary captures insights from a panel of global experts across biotech, pharma, and clinical research, exploring how sponsors can accelerate development by leveraging these markets.
What You’ll Learn
Download this executive summary to discover:
- Key challenges in early-phase oncology trials
Including communication barriers, protocol complexity, and investigator burden that can delay progress. - Why South Korea and Taiwan stand out
From globally aligned investigators and high patient compliance to centralized patient databases and efficient recruitment strategies. - Regulatory considerations and how to navigate them
Practical insights into evolving regulatory expectations and strategies to mitigate approval delays. - The role of local CRO expertise
How partnering with experienced regional teams can streamline operations and improve trial outcomes.
For biotech and pharmaceutical companies developing oncology therapies, early-stage decisions can define long-term success. Choosing the right geography—and the right partner—can accelerate timelines, improve data quality, and reduce risk.
South Korea and Taiwan offer a compelling combination of:
- Highly engaged and globally trained investigators
- Access to diverse and compliant patient populations
- Strong clinical infrastructure with efficient enrollment capabilities
This executive summary is based on a virtual roundtable discussion featuring leaders from:
- Acrotech Biopharma
- NextPoint Therapeutics
- Pilatus Biosciences
- Asan Medical Center (University of Ulsan College of Medicine)
- CMIC Korea & CMIC Asia-Pacific
Moderated by Citeline, the discussion provides real-world perspectives on accelerating oncology development in emerging APAC hubs.
-> View CMIC Solutions in APAC
